Introduction/Background Gemcitabine or liposomal doxorubicin are well-accepted chemotherapy modilities in management of recurrent high grade serous ovarian cancer (HG-SOC) with partial platinum response. In this study we aimed to evaluate the progression free intervals after the secondline gemcitabine or liposomal doxorubicin treatments in this group.
Methodology This is a descriptive retrospective study including 67 patients with recurrent high grade serous ovarian cancer (HG-SOC) with partial platinum response. Partial response was defined as recurrence after 6 first-line therapies with platine derives in 6–12months. Patients who underwent gemcitabine + platine derives ± bevacizumab was defined as Group I and liposomal doxorubicin + platine derives ± bevacizumab as Group II.
Results The median recurrence time of the whole group was 8 months. The mean initial recurrence times were 7.4±2.6 and 8.5±2.3 months for group I and II, respectively. The mean progression free survival time after in Group I and II were 13.6±6.1 and 13.7±19.7 months, (p:0.344), respectively. The estimated overall survival for groups were 59.0±7.2 months and 45.7±3.5 months but this was not statistically significant (p:0.135).
Conclusion In our study, we found that progression free intervals after the secondline gemcitabine or liposomal doxorubicin treatments in patients recurrent high grade serous ovarian cancer (HG-SOC) with partial platinum response are similar. This finding may support use of liposomal doxorubicin with longer treatment intervals and less hospital admission for the patient.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.